Cullinan Therapeutics, Inc. CGEM
11.35 USD +0.12 (+1.07%)
At closeNov 11, 2026, 4:42 PM EST
11.35 0.00 0.00%
After hours · Nov 11, 4:42 PM ET
11.15 Day range 11.68
7.72 52-week range 23.19
- YTD
- +9.66%
- 1 year
- +45.51%
News
benzinga.com Wedbush Maintains Outperform on Cullinan Therapeutics, Raises Price Target to $44 Wedbush analyst Robert Driscoll maintains Cullinan Therapeutics (NASDAQ:CGEM) with a Outperform and raises the price target from $42 to $44.
benzinga.com Cullinan Therapeutics Q3 EPS $(0.74) Beats $(0.84) Estimate Cullinan Therapeutics (NASDAQ:CGEM) reported quarterly losses of $(0.74) per share which beat the analyst consensus estimate of $(0.84) by 11.9 percent. This is a 3.9 percent increase over losses of…
globenewswire.com Cullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2026 Financial Results CLN-978 (CD19 TCE) multi-dose regimen data in SLE, RA, and Sjögren's disease will be shared in December Velinotamig (BCMA TCE) data presented at ACR Convergence 2026; global Phase 1/2 study in…
globenewswire.com Cullinan Therapeutics to Participate in Upcoming Investor Conferences CAMBRIDGE, Mass., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class,…
benzinga.com Reported Sunday, Cullinan Therapeutics Reports Velinotamig Achieved Clinically Meaningful Disease Activity Improvement In 8 Of 9 Evaluable Refractory Lupus Patients, With Four Complete Renal Responses, In Data Presented At ACR Convergence 2026 Clinically meaningful improvement in disease activity among 8 of 9 evaluable patients, including rapid and marked reductions in proteinuria with complete renal responses Deep and sustained reduction…
globenewswire.com Velinotamig, a BCMAxCD3 T Cell Engager, Achieves Complete Renal Responses and Significantly Reduces Disease Activity in Systemic Lupus Erythematosus in Data Presented at ACR Convergence 2026 Clinically meaningful improvement in disease activity among 8 of 9 evaluable patients, including rapid and marked reductions in proteinuria with complete renal responses
globenewswire.com Cullinan Therapeutics Announces Presentations for CLN-049, a FLT3 T Cell Engager, and Velinotamig, a BCMA T Cell Engager, at the 68th ASH Annual Meeting CAMBRIDGE, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class,…
benzinga.com BTIG Maintains Buy on Cullinan Therapeutics, Raises Price Target to $41 BTIG analyst Julian Harrison maintains Cullinan Therapeutics (NASDAQ:CGEM) with a Buy and raises the price target from $40 to $41.
benzinga.com Cullinan Therapeutics Gets FDA And Australian Therapeutic Goods Administration Clearance To Initiate Its Global Phase 1b/2a Clinical Trial In Adults With Relapsing And Refractory ITP And Warm Autoimmune Hemolytic Anemia Global regulatory clearances in the U.S. and Australia support initiation of a Phase 1b/2a study in relapsing and refractory ITP and wAIHAStudy expands immunology portfolio into autoimmune…
benzinga.com BTIG Reiterates Buy on Cullinan Therapeutics, Maintains $40 Price Target BTIG analyst Julian Harrison reiterates Cullinan Therapeutics (NASDAQ:CGEM) with a Buy and maintains $40 price target.- benzinga.com Taiho Oncology and Cullinan Therapeutics Say Data From Cohort C Of Phase 2 REZILIENT2 Trial Of Zipalertinib For Locally Advanced Or Metastatic Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Or Uncommon EGFR Mutations and Active CNS Metastases Shows Intracranial Objective Response Rate Of 30.2% In 43 Evaluable Patients Taiho Oncology, Inc. and Cullinan Therapeutics, Inc. (NASDAQ:CGEM) today announced results from Cohort C of the Phase 2 REZILIENT2 trial evaluating zipalertinib monotherapy in patients with locally…
- benzinga.com HC Wainwright & Co. Reiterates Buy on Cullinan Therapeutics, Maintains $35 Price Target HC Wainwright & Co. analyst Robert Burns reiterates Cullinan Therapeutics (NASDAQ:CGEM) with a Buy and maintains $35 price target.
- benzinga.com Reported Earlier, Cullinan Therapeutics Initiates NDA Submission For Zipalertinib Plus Chemotherapy In First-Line EGFR Exon 20 Insertion NSCLC Under FDA RTOR Program After Phase 3 REZILIENT3 Trial Met Primary Endpoint In the Phase 3 REZILIENT3 study, zipalertinib combination therapy demonstrated longest median progression-free survival observed to date in first-line EGFR exon20ins NSCLC After agreement with the…
- benzinga.com HC Wainwright & Co. Maintains Buy on Cullinan Therapeutics, Raises Price Target to $35 HC Wainwright & Co. analyst Robert Burns maintains Cullinan Therapeutics (NASDAQ:CGEM) with a Buy and raises the price target from $30 to $35.
benzinga.com BTIG Reiterates Buy on Cullinan Therapeutics, Maintains $40 Price Target BTIG analyst Julian Harrison reiterates Cullinan Therapeutics (NASDAQ:CGEM) with a Buy and maintains $40 price target.- benzinga.com BTIG Maintains Buy on Cullinan Therapeutics, Raises Price Target to $40 BTIG analyst Julian Harrison maintains Cullinan Therapeutics (NASDAQ:CGEM) with a Buy and raises the price target from $39 to $40.
benzinga.com Reported Sunday, Taiho And Cullinan's REZILIENT3 Trial Meets Primary Endpoint, Zipalertinib Combination Shows PFS Hazard Ratio Of 0.50 Versus Chemotherapy Alone Results from the Phase 3 REZILIENT3 trial were featured in a Presidential Symposium at WCLC 2026 and demonstrated a statistically significant improvement in progression-free survival in first-line…- benzinga.com Cullinan Therapeutics To Present Positive Phase 3 REZILIENT3 Results For Zipalertinib In EGFR Exon 20+ Lung Cancer; To Host A Virtual Event On Monday, September 14, 2026, At 8:00 a.m. ET Results from the planned interim analysis of the Phase 3 REZILIENT3 trial of zipalertinib plus chemotherapy in first-line EGFR exon 20 insertion mutation NSCLC to be presented in Presidential…
- benzinga.com Taiho Oncology And Cullinan Therapeutics Say Results From Planned Interim Analysis Of Phase 3 REZILIENT3 Trial Selected For Presentation In Presidential Symposium 2 At IASLC 2026 World Conference On Lung Cancer Presentation will feature results from the planned interim analysis of the Phase 3 REZILIENT3 trial, which met its primary endpoint of progression-free survival in first line EGFR exon 20 insertion…
- benzinga.com HC Wainwright & Co. Reiterates Buy on Cullinan Therapeutics, Maintains $30 Price Target HC Wainwright & Co. analyst Robert Burns reiterates Cullinan Therapeutics (NASDAQ:CGEM) with a Buy and maintains $30 price target.
benzinga.com Cullinan Therapeutics Zipalertinib Combo Clears Key Phase 3 Hurdle As First-Line Lung Cancer Treatment Option Takes Shape Cullinan Therapeutics and Taiho report positive Phase 3 trial results for zipalertinib in treating advanced lung cancer.- benzinga.com Wedbush Maintains Outperform on Cullinan Therapeutics, Raises Price Target to $42 Wedbush analyst Robert Driscoll maintains Cullinan Therapeutics (NASDAQ:CGEM) with a Outperform and raises the price target from $39 to $42.
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session Gainers Liminatus Pharma (NASDAQ:LIMN) stock moved upwards by 55.9% to $0.17 during Thursday's pre-market session. The company's market cap stands at $7.2 million. LENSAR (NASDAQ:LNSR) shares…- benzinga.com Cullinan Therapeutics Q2 EPS $(0.81) Beats $(0.85) Estimate Cullinan Therapeutics (NASDAQ:CGEM) reported quarterly losses of $(0.81) per share which beat the analyst consensus estimate of $(0.85) by 4.71 percent. This is a 24.3 percent increase over losses of…
- benzinga.com BTIG Maintains Buy on Cullinan Therapeutics, Raises Price Target to $39 BTIG analyst Julian Harrison maintains Cullinan Therapeutics (NASDAQ:CGEM) with a Buy and raises the price target from $38 to $39.
- benzinga.com Cullinan Therapeutics Announces Positive Feedback From FDA Following End-Of-Phase 1 Meeting For CLN-049, FLT3xCD3 T Cell Engager Being Evaluated In Patients With Acute Myeloid Leukemia Cullinan Therapeutics, Inc. (NASDAQ:CGEM, "Cullinan"))), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, disease-modifying T cell engagers in autoimmune…
- benzinga.com Wedbush Reiterates Outperform on Cullinan Therapeutics, Maintains $37 Price Target Wedbush analyst Robert Driscoll reiterates Cullinan Therapeutics (NASDAQ:CGEM) with a Outperform and maintains $37 price target.
- benzinga.com Cullinan Therapeutics Reports Clinical Data And Outlines Global Clinical Development Plans For CLN-978, CD19xCD3 T Cell Engager, And Velinotamig, BCMAxCD3 T Cell Engager CLN-978 (CD19 TCE) EULAR data demonstrated potential for immune reset, including remissions, in both systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA)CLN-978 data from the first RA…
- benzinga.com HC Wainwright & Co. Reiterates Buy on Cullinan Therapeutics, Maintains $30 Price Target HC Wainwright & Co. analyst Robert Burns reiterates Cullinan Therapeutics (NASDAQ:CGEM) with a Buy and maintains $30 price target.
benzinga.com Why Marvell Technology Shares Are Trading Higher By 7%; Here Are 20 Stocks Moving Premarket href=https://www.benzinga.com/quote/RMSG target=_blank>(NASDAQ: RMSG) lost 67.6% to $0.69 in pre-market trading. The company recently announced a 1-for-20 reverse stock split.The shares of Marvell…- benzinga.com Reported Saturday, Cullinan's CLN-978 Delivers Deep B Cell Depletion And Clinical Remissions In SLE And RA Patients Following Single Target Dose In Phase 1 Trial Clinical benefit, including remissions, demonstrated in both systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) patients following a single target dose of CLN-978 Deep, dose-dependent B…
- benzinga.com Cullinan Therapeutics To Host An Immunology Day Event in New York City For Analysts And Institutional Investors On June 10 New and updated clinical data to be presented from over 30 patients across systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) studiesInitial data from the first multi-dose cohort of RA…
- benzinga.com The FDA Grants Orphan Drug Designation To Cullinan Therapeutics' CLN-049 For Relapsed/Refractory Acute Myeloid Leukemia Cullinan Therapeutics, Inc. (NASDAQ:CGEM), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, high-impact therapies in autoimmune diseases and cancer, today…
- benzinga.com BTIG Reiterates Buy on Cullinan Therapeutics, Maintains $38 Price Target BTIG analyst Julian Harrison reiterates Cullinan Therapeutics (NASDAQ:CGEM) with a Buy and maintains $38 price target.
- benzinga.com Cullinan Therapeutics To Reveal Initial Clinical Data for CLN-978 in Treatment-Refractory Rheumatoid Arthritis and Systemic Lupus Erythematosus at EULAR 2026 Congress Cullinan Therapeutics, Inc. (NASDAQ:CGEM), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, high-impact therapies in autoimmune diseases and cancer, today…
- benzinga.com Wedbush Maintains Outperform on Cullinan Therapeutics, Raises Price Target to $37 Wedbush analyst Robert Driscoll maintains Cullinan Therapeutics (NASDAQ:CGEM) with a Outperform and raises the price target from $36 to $37.
- benzinga.com Cullinan Therapeutics Q1 EPS $(0.75) Beats $(0.87) Estimate Cullinan Therapeutics (NASDAQ:CGEM) reported quarterly losses of $(0.75) per share which beat the analyst consensus estimate of $(0.87) by 13.79 percent. This is a 1.35 percent decrease over losses…
benzinga.com Global Business Travel Group Posts Upbeat Q1 Results, Joins Cabaletta Bio, Aura Biosciences And Other Big Stocks Moving Higher On Monday Global Business Travel Group Inc (GBTG), a NYSE-listed company, saw its stock rise 57% on Monday after reporting better-than-expected financial results. Other top gainers included companies like…- benzinga.com BTIG Reiterates Buy on Cullinan Therapeutics, Maintains $38 Price Target BTIG analyst Julian Harrison reiterates Cullinan Therapeutics (NASDAQ:CGEM) with a Buy and maintains $38 price target.
- benzinga.com HC Wainwright & Co. Maintains Buy on Cullinan Therapeutics, Raises Price Target to $30 HC Wainwright & Co. analyst Robert Burns maintains Cullinan Therapeutics (NASDAQ:CGEM) with a Buy and raises the price target from $27 to $30.
- benzinga.com Cullinan Therapeutics Files Prospectus For Offering Mixed Shelf; Terms Undisclosed https://www.sec.gov/Archives/edgar/data/1789972/000119312526183596/d587157ds3asr.htm
- benzinga.com Taiho, Cullinan Announce Zipalertinib NDA Accepted By FDA For NSCLC Harboring EGFR ex20ins Mutations; PDUFA Date Set Feb. 27, 2027 NDA submission based on the Phase 2b REZILIENT1 clinical trial, which demonstrated clinically meaningful and durable responses in patients with relapsed EGFR exon 20 insertion–mutated…
benzinga.com Wedbush Maintains Outperform on Cullinan Therapeutics, Raises Price Target to $36 Wedbush analyst Robert Driscoll maintains Cullinan Therapeutics (NASDAQ:CGEM) with a Outperform and raises the price target from $34 to $36.
benzinga.com Cullinan Therapeutics: Q4 Earnings Insights - benzinga.com Cullinan Therapeutics Q4 EPS $(0.77) Beats $(0.82) Estimate Cullinan Therapeutics (NASDAQ:CGEM) reported quarterly losses of $(0.77) per share which beat the analyst consensus estimate of $(0.82) by 6.1 percent. This is a 5.48 percent decrease over losses of…
benzinga.com Citigroup Initiates Coverage On Cullinan Therapeutics with Buy Rating, Announces Price Target of $33 Citigroup analyst Samantha Semenkow initiates coverage on Cullinan Therapeutics (NASDAQ:CGEM) with a Buy rating and announces Price Target of $33.- benzinga.com Guggenheim Initiates Coverage On Cullinan Therapeutics with Buy Rating, Announces Price Target of $30 Guggenheim analyst Brad Canino initiates coverage on Cullinan Therapeutics (NASDAQ:CGEM) with a Buy rating and announces Price Target of $30.
- benzinga.com HC Wainwright & Co. Maintains Buy on Cullinan Therapeutics, Raises Price Target to $27 HC Wainwright & Co. analyst Robert Burns maintains Cullinan Therapeutics (NASDAQ:CGEM) with a Buy and raises the price target from $26 to $27.
- benzinga.com Wedbush Maintains Outperform on Cullinan Therapeutics, Raises Price Target to $34 Wedbush analyst Robert Driscoll maintains Cullinan Therapeutics (NASDAQ:CGEM) with a Outperform and raises the price target from $25 to $34.
benzinga.com Paramount Skydance, Wave Life Sciences, Ocular Therapeutix, Carvana And Other Big Stocks Moving Higher On Monday